Phio Pharmaceuticals Corp. Earnings Per Share Disclosure
9. Net Loss per Share Attributable to Common Stockholders
The following table sets forth the potential common shares excluded from the calculation of net loss per common share attributable to common stockholders because their inclusion would be anti-dilutive:
| December 31, | ||||||||
| 2017 | 2016 | |||||||
|
Options to purchase common stock |
50,156 | 37,444 | ||||||
|
Common stock underlying Series B Convertible Preferred Stock |
— | 637,444 | ||||||
|
Warrants to purchase common stock |
1,408,000 | 1,408,046 | ||||||
|
|
|
|
|
|||||
|
Total |
1,458,156 | 2,082,934 | ||||||
|
|
|
|
|
|||||
Want the next Phio Pharmaceuticals Corp. earnings per share disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Phio Pharmaceuticals Corp.'s next filing hits EDGAR. No credit card, your email never gets sold.
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.